If you or someone you care for takes antihistamines regularly, here is the short answer: second-generation antihistamines like cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra) are safer for your brain than first-generation options like diphenhydramine (Benadryl). The reason comes down to chemistry. First-generation antihistamines are highly lipophilic and readily cross the blood-brain barrier, causing sedation and cognitive impairment. They also block muscarinic acetylcholine receptors — the same neurotransmitter system that deteriorates in Alzheimer’s disease. A landmark 2015 study published in JAMA Internal Medicine found that cumulative use of anticholinergic drugs, including diphenhydramine, was associated with up to a 54 percent increased risk of dementia at the highest cumulative doses.
Second-generation antihistamines have minimal central nervous system penetration and are highly selective for H1 receptors only, which is why they rarely cause drowsiness or cognitive dulling. This distinction matters enormously for older adults and anyone concerned about long-term brain health. Consider a common scenario: a 68-year-old woman takes Benadryl every night to help her sleep, something her doctor never specifically prescribed but never questioned either. She has been doing this for years. That cumulative anticholinergic exposure is exactly the pattern researchers have flagged as concerning. This article breaks down how these two classes of antihistamines differ in their mechanisms, what the dementia research actually shows and where it falls short, a recent FDA warning about certain second-generation drugs, and practical guidance for making safer choices — especially for people already at risk for cognitive decline.
Table of Contents
- What Makes First-Generation Antihistamines Different From Second-Generation Ones?
- What Does the Dementia Research Actually Show — and Where Does It Fall Short?
- The Anticholinergic Burden Problem in Dementia Care
- Choosing the Right Antihistamine — A Practical Comparison
- The 2025 FDA Warning on Cetirizine and Levocetirizine Withdrawal
- What Caregivers Should Watch For
- Where the Science Is Heading
- Conclusion
- Frequently Asked Questions
What Makes First-Generation Antihistamines Different From Second-Generation Ones?
Both first-generation and second-generation antihistamines work by blocking H1 histamine receptors, which are responsible for the sneezing, itching, and runny nose that come with allergic reactions. The critical difference is selectivity. First-generation agents like diphenhydramine, chlorpheniramine (Chlor-Trimeton), clemastine (Tavist), hydroxyzine (Vistaril), and doxylamine (Unisom) do not limit themselves to H1 receptors. They also block muscarinic acetylcholine receptors, alpha-adrenergic receptors, and serotonin receptors. this lack of selectivity is what produces their broad side effect profile: drowsiness, dizziness, blurred vision, dry mouth, urinary retention, constipation, and reduced coordination and reaction speed. Less common but documented effects include palpitations, hypotension, hallucinations, and psychosis. Second-generation antihistamines — cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra), levocetirizine (Xyzal), desloratadine (Clarinex), and azelastine (Astelin) — were designed to fix those problems.
They are highly selective for H1 receptors only and have minimal penetration into the central nervous system. Their side effects are generally limited to mild drowsiness, fatigue, headache, nausea, and occasional dry mouth. They are far better tolerated overall. There is also a practical difference in dosing. First-generation antihistamines are short-acting, typically lasting only 4 to 6 hours per dose, which means people often take them multiple times daily. Second-generation drugs last 12 to 24 hours, so a single daily dose usually suffices. This matters for cumulative exposure calculations — the more frequently you dose, the faster anticholinergic burden accumulates.
What Does the Dementia Research Actually Show — and Where Does It Fall Short?
The most cited study on this topic is Gray et al., published in 2015 in JAMA Internal Medicine. It was a prospective cohort study that tracked cumulative anticholinergic use — including first-generation antihistamines — and found an adjusted hazard ratio of 1.54 (95 percent confidence interval: 1.21 to 1.96) for dementia at the highest cumulative dose levels. In plain language, people with the heaviest long-term anticholinergic use had roughly a 54 percent higher risk of developing dementia compared to those with minimal use. More recently, a 2024 study in The Journal of allergy and Clinical Immunology: In Practice confirmed that patients with allergic rhinitis using first-generation antihistamines face escalating dementia risk with increasing cumulative dosage, and that the risk was higher with first-generation agents than with second-generation ones. However, there is an important caveat that often gets lost in headlines. As Harvard Health has noted, while several studies suggest a link between anticholinergic drugs and dementia, others have found no risk, and all current studies have inherent limitations. These are observational studies, not randomized controlled trials.
They cannot prove causation. It is possible, for instance, that people who take more benadryl have underlying sleep disorders or chronic conditions that independently raise dementia risk. Researchers have tried to control for these confounders, but no observational study can eliminate them entirely. What this means in practice is that no physician can tell you with certainty that diphenhydramine caused or will cause dementia in a specific patient. But the weight of evidence is strong enough that major medical organizations, including the American Academy of Allergy, Asthma, and Immunology, now advise against routine use of first-generation antihistamines. The risk-benefit calculation has shifted. When equally effective and safer alternatives exist, continuing to use drugs with documented anticholinergic burden — particularly in older adults — is difficult to justify.
The Anticholinergic Burden Problem in Dementia Care
For families managing dementia or mild cognitive impairment, the anticholinergic question is not abstract. Many people with early dementia are prescribed cholinesterase inhibitors like donepezil (Aricept) to boost acetylcholine activity in the brain. Taking a first-generation antihistamine at the same time works against that medication by blocking the very same neurotransmitter the drug is trying to preserve. It is the pharmacological equivalent of pressing the gas and brake pedals simultaneously. This problem extends beyond antihistamines.
The concept of anticholinergic burden considers the total load of all anticholinergic medications a person takes. A patient might be on a first-generation antihistamine for allergies, an anticholinergic bladder medication like oxybutynin for incontinence, and a tricyclic antidepressant — each one adding to the cumulative anticholinergic effect. Geriatricians and pharmacists increasingly perform anticholinergic burden assessments as part of medication reviews, and first-generation antihistamines are among the easiest drugs to swap out for safer alternatives. A specific example: a man in his seventies with seasonal allergies and early-stage Alzheimer’s disease had been taking diphenhydramine nightly for years, partly for allergies and partly because it helped him fall asleep. His neurologist flagged the medication during a routine review and switched him to fexofenadine for daytime allergies and a non-anticholinergic sleep approach. Cases like this are common in geriatric medicine, and the fix is often straightforward.
Choosing the Right Antihistamine — A Practical Comparison
For most people, especially those over 65 or those with any cognitive concerns, the choice is straightforward: start with a second-generation antihistamine. Current evidence-based clinical guidelines, including those published in the Annals of Allergy, Asthma, and Immunology in 2023, recommend second-generation antihistamines as first-line therapy for allergic rhinitis and urticaria due to their superior efficacy-to-side-effect ratio. Among second-generation options, there are tradeoffs worth understanding. Fexofenadine (Allegra) is considered the least sedating of the group and does not cross the blood-brain barrier at all in most studies, making it perhaps the safest choice for people worried about cognitive effects. Loratadine (Claritin) is also minimally sedating. Cetirizine (Zyrtec) and levocetirizine (Xyzal) are slightly more potent for symptom control but carry a small risk of drowsiness — and as discussed below, a recently identified withdrawal concern.
None of these drugs have meaningful anticholinergic activity. First-generation antihistamines still have legitimate niche uses. Dimenhydrinate (Dramamine) remains a go-to for motion sickness. Doxylamine and diphenhydramine are FDA-approved as over-the-counter sleep aids for short-term use. Hydroxyzine is sometimes prescribed for acute anxiety or as a pre-surgical sedative. In emergency departments, diphenhydramine is used for acute allergic reactions. The issue is not that these drugs should never be used — it is that they should not be the default choice for chronic, everyday allergy management, particularly in older adults.
The 2025 FDA Warning on Cetirizine and Levocetirizine Withdrawal
Second-generation antihistamines are not without their own emerging concerns. On May 16, 2025, the FDA issued a Drug Safety Communication warning that stopping cetirizine (Zyrtec) or levocetirizine (Xyzal) after long-term use may cause rare but severe itching — called pruritus — within days of discontinuation. Between 2017 and 2023, the FDA received 209 worldwide reports of pruritus after stopping cetirizine (180 cases), levocetirizine (27 cases), or both (2 cases). The symptoms most commonly appeared after three or more months of daily use, though some cases occurred after just one month. The itching could be intense enough to significantly disrupt daily life, but restarting the antihistamine and then gradually tapering the dose resolved symptoms in most patients.
The FDA now requires updated prescribing information for these drugs and recommends that clinicians discuss this risk with patients before starting chronic use. This warning does not change the overall safety calculus — 209 cases worldwide over six years is genuinely rare, and the condition is manageable with a taper. But it does highlight an important principle: no medication is entirely without risk, and any drug used daily for months or years deserves periodic reassessment. If you have been taking Zyrtec or Xyzal daily for an extended period, do not stop abruptly. Talk to your doctor about a gradual reduction if you want to discontinue.
What Caregivers Should Watch For
Caregivers of people with dementia should review all medications — prescription and over-the-counter — for anticholinergic activity. This is especially important because many older adults self-medicate with over-the-counter products containing diphenhydramine without realizing the potential cognitive impact. Benadryl is in nighttime cold formulas, sleep aids like Tylenol PM, and some anti-itch creams that can be absorbed systemically.
A caregiver doing a medicine cabinet audit might be surprised to find two or three products containing first-generation antihistamines. Ask the prescribing physician or pharmacist to calculate the total anticholinergic burden for the person in your care. If first-generation antihistamines are on the list, ask whether a second-generation alternative or a non-drug approach could work instead. This single medication change can be one of the easiest and most impactful interventions in a dementia care plan.
Where the Science Is Heading
Research into the anticholinergic-dementia connection is ongoing, and future studies may clarify whether the relationship is truly causal or whether it reflects underlying vulnerabilities. Large-scale prospective trials with better controls for confounders are needed, though the ethical constraints of randomizing people to potentially harmful long-term drug exposure make traditional clinical trials difficult to design. Observational data will likely remain the primary evidence base for some time.
Meanwhile, the pharmaceutical industry continues to refine antihistamine design. Newer formulations aim for even greater H1 selectivity and reduced off-target effects. For now, the practical takeaway remains clear: if you or someone you care for uses antihistamines regularly, second-generation options are the safer choice for brain health, and first-generation agents should be reserved for short-term, specific situations where their unique properties are genuinely needed.
Conclusion
The difference between first-generation and second-generation antihistamines is not a minor pharmacological footnote — it has real implications for brain health, particularly in older adults and people at risk for dementia. First-generation drugs like diphenhydramine cross the blood-brain barrier, block acetylcholine receptors, and have been associated with increased dementia risk at high cumulative doses. Second-generation options like fexofenadine, loratadine, and cetirizine are highly selective for H1 receptors, cause minimal cognitive effects, and are recommended as first-line therapy by current clinical guidelines.
If you are caring for someone with cognitive concerns, audit their medicine cabinet for hidden sources of anticholinergic drugs, including over-the-counter sleep aids and cold formulas. Talk to their doctor about switching to second-generation alternatives. Be aware of the 2025 FDA warning about cetirizine and levocetirizine withdrawal itching, and do not stop those drugs abruptly after long-term use. These are small, concrete steps that can meaningfully reduce anticholinergic burden — one of the few modifiable risk factors in the dementia equation.
Frequently Asked Questions
Is it safe to take Benadryl occasionally if I’m worried about dementia?
Occasional use of diphenhydramine — such as once or twice for an acute allergic reaction — is unlikely to meaningfully increase dementia risk. The research that found elevated risk focused on high cumulative doses taken over years. The concern is with regular, long-term use, not a single dose during an allergy flare.
Which second-generation antihistamine has the least sedation?
Fexofenadine (Allegra) is generally considered the least sedating second-generation antihistamine. It does not meaningfully cross the blood-brain barrier in most studies. Loratadine (Claritin) is also minimally sedating. Cetirizine (Zyrtec) can cause mild drowsiness in some people.
Can I stop taking Zyrtec cold turkey?
If you have been taking cetirizine (Zyrtec) or levocetirizine (Xyzal) daily for a month or more, the FDA warns that stopping abruptly may cause rare but severe itching. Talk to your doctor about tapering gradually rather than stopping all at once.
Should someone with dementia stop all antihistamines?
Not necessarily. Second-generation antihistamines have minimal anticholinergic activity and are generally considered safe. The concern is specifically with first-generation antihistamines that block acetylcholine receptors. Any medication changes should be discussed with the person’s physician.
Do anticholinergic drugs cause dementia or just increase risk?
Current research shows an association, not proven causation. The 2015 Gray et al. study and the 2024 follow-up study found increased dementia risk with cumulative anticholinergic use, but these were observational studies with inherent limitations. Harvard Health notes that some studies have found no risk. The evidence is strong enough to warrant caution, but it cannot definitively prove that these drugs cause dementia.
Are there any first-generation antihistamines that are safer for the brain?
All first-generation antihistamines cross the blood-brain barrier and have anticholinergic properties to varying degrees. There is no first-generation option that avoids these effects entirely. If brain safety is a priority, switching to a second-generation antihistamine is the most reliable approach.
